Kornimate/medical-research-clean huggingface dataset:
net for sgbv survivors in eastern dr congo

Conditions: Posttraumatic Stress Disorder; Shame

Summary: throughout the last 10 years narrative exposure therapy (net) has evolved as one of the most effective, culturally sensitive trauma interventions. in the present study the effectiveness of net delivered by trained health personnel in a sample of survivors of sexual and gender based violence (sgbv) who suffer from posttraumatic stress disorder (ptsd) will be assessed. structured baseline, 3 and 6 month follow up interviews will be administered to assess the main outcome measures ptsd and shame. the trial will take place in goma, dr congo, where sgbv and its sequelae has been a major problem.

participants will be recruited through local ngos and eligible clients randomized to the treatment (net; app. n=100) or treatment-as-usual control (app. n=100) group, respectively. at baseline, 3-month and 6-month post-treatment, sociodemographic data, trauma exposure - esp. sgbv, ptsd, dissociation, shame, functionality and depression will be assessed in a structured interview. the interviews will be conducted by blind congolese psychological interviewers after an intensive 3-weeks training and continuous supervision.

Eligibility criteria:
inclusion criteria: * sgbv survivors (event happened more than 4 weeks ago) * ptsd diagnosis (dsm-5) exclusion criteria: * acute psychosis * signs of cerebro-organic disease * acute drug or alcohol intoxication

Keywords: ptsd shame narrative exposure therapy sexual and gender based violence (sgbv) dr congo
the clinical significance of gut permeability in gastrointestinal post acute covid-19 syndrome

Conditions: Gastrointestinal Post Acute COVID-19 Syndrome

Summary: severe acute respiratory syndrome coronavirus 2 (sars- cov-2) and the associated coronavirus disease 2019 (covid-19) have been spreading all around the world for past 3 years. some of these convalescent individuals experienced long- term sequelae termed 'long covid', or 'post- acute covid-19 syndrome'(pacs). common manifestations are systemic, neuropsychiatric, cardio- respiratory and gastrointestinal \[1\]. the prevalence of gastrointestinal pacs was 2-5% in different literatures \[2\]\[3\]. the risk factors of gastrointestinal pacs include anosmia, ageusia, and presence of chronic bowel disease, dyspeptic symptoms and the psychological comorbidity \[4\]. previous articles have discussed pathogenesis of pacs, which was associated with increasing serum cytokine level and persisted inflammatory status \[5\]. whereas, the influence of chronic inflammation to target organ has not been well studied. liu et al explored the gut microbiota dynamics in patients with pacs, which revealed higher levels of ruminococcus gnavus, bacteroides vulgatus and lower levels of faecalibacterium prausnitzii \[6\]. another article established the association between multisystem inflammatory syndrome in children (mis-c) and zonulin-dependent loss of gut mucosal barrier \[7\]. according to previous studies, infectious enteritis may cause subsequent post infectious irritable bowel syndrome \[8\]\[9\], which was associated with increased gut permeability, t-lymphocyte, mast cell and proinflammatory cytokine \[10\]\[11\]. it is reasonable that gastrointestinal pacs might be also associated with dysfunction of gut mucosal barrier. confocal laser endomicroscopy (cle) is a new endoscopic imaging tool that enables visualization of gut mucosa changes. the gut permeability could be accessed by cle in patient with irritable bowel syndrome \[12\]. this study aimed to explore the association between gut permeability and gastrointestinal pacs.


Eligibility criteria:
inclusion criteria: * persisted gastrointestinal symptoms such as dyspepsia, abdomen pain, diarrhea or constipation 3 months after covid-19 infection exclusion criteria: * terminal cancer, surgical history of gastrointestinal tract, acute gastrointestinal tract bleeding, allergy to fluorescein, pregnant or breast feeding, helicobacter pylori infection, major cardiopulmonary disease, liver cirrhosis, end stage renal disease, autoimmune disease, inflammtory bowel disease, small intestinal bacterial overgrowth, celiac disease, type 1 diabetic mellitus, type ii diabetic mellitus, gastroenteritis in 3 months, history of irritable bowel syndrome, usage of nsaid, steroid

Keywords: post acute covid-19 syndrome gut permeability confocal laser endomicroscopy
patient guided psychiatric admissions

Conditions: Schizophrenia; Bipolar Disorder

Summary: to meet the requirement for increased patient involvement, several community mental health centres (cmhc) have initiated a service called "patient-guided admissions". the investigators will compare a group with "patient guided admission/self-referral to inpatient beds" with a group having treatment as usual. it is expected that patients in the intervention group will experience more increased feeling of coping (patient activation) after 4 months and 12 months as a result of participating in "patient-guided admissions" than patients getting treatment as usual. in addition the total number of inpatient days either in the cmhc, psychiatric hospital or community rehabilitation centre is expected to be clearly lower in the intervention group than in the 'treatment-as-usual' group during one year after intake. also the number of involuntary admissions either as inpatient or outpatient will be significant lower in the intervention group than the 'treatment-as-usual' group.the number of admissions in cmhc and psychiatric hospital, as well as the number of outpatient consultations in primary care, cmhc and psychiatric hospitals, will be lower in the intervention group than in the 'treatment-as-usual' group. patients in the intervention group will experience improved mental health, increased feeling of coping (patient activation) and increased experience of recovery after 4 months and 12 months as a result of participating in "patient-guided admissions".

participants will be patients with psychosis or bipolar disorders. patients in the intervention group will have a contract on "self-referral to inpatient beds" for one year. they can call the cmhc directly and ask for a bed for until 5 nights. the patients in the 'treatment-as-usual' group will follow common procedures by either contacting their general practitioner, emergency department or duty doctor, and they will be offered a "self-referral to inpatient bed" contract after a year if they satisfy the inclusion criteria. regardless of the participation in the intervention group, the patients can also be ordinary admitted during the project period by a doctor via regular procedures in both hospital and cmhc if there is a need for this. all admissions will appear in the register data.

Eligibility criteria:
inclusion criteria: * schizophrenia or bipolar disorder * long term care * established relationship with the ward exclusion criteria: * extensive substance use problems * self-destructive behavior * not able to consent

Keywords: schizophrenia bipolar disorder long term care patient admission
prkaa2 genetic polymorphisms and its susceptibility to chinese type 2 diabetes mellitus and diabetic nephropathy

Conditions: T2DM (Type 2 Diabetes Mellitus)

Summary: metformin is a classical oral antidiabetic drug, often recommended to be the first-choice treatment of type 2 diabetes mellitus (t2dm). based on the previous research on prkaa2, stk11 and diabetes, this study aimed to investigate the distributive characteristic of prkaa2 and stk11 polymorphisms and the potential influence of stk11polymorphisms on metformin efficacy among chinese t2dm patients, discuss the association of prkaa2 polymorphisms between t2dm patients and healthy subjects.


Eligibility criteria:
inclusion criteria: * diagnosed with t2dm in keeping with the who criteria in 1999 \[14\], with fasting blood glucose (fbg) ≥ 7.0mmol ⁄ l and ⁄ or postprandial blood glucose (pbg) ≥ 11.1mmol ⁄ l; not using other antidiabetic drugs within the experimental period. exclusion criteria: * other significant illness such as cancer, myocardial infarction, stroke, severe liver, and kidney disease

Keywords: t2dm genetic polymorphism diabetic nephropathy
clinical evaluation in real life of tlc-nosf dressings in the local treatment of chronic wounds (dfu and vlu)

Conditions: Real Life Study; TLC-NOSF Dressings; Venous Leg Ulcer; Diabetic Foot Ulcer; QoL Questionnaire

Summary: the objective of this study is to document the performance and the safety of urgostart plus® border, urgostart plus® pad and urgostart interface® in the local treatment of diabetic foot ulcers (neuropathic or neuroischemic - non-critical ischemia) and venous or mixed predominantly venous leg ulcers, in real life conditions and current practice, in france.

this is an observational, non-interventional, prospective multicenter study, carried out in real-life conditions on ce marked medical devices used for their intended purpose. the study will be carried out in france, in accordance with national and european regulations (rdm 2017/745).

Eligibility criteria:
inclusion criteria: * adult outpatient having signed informed consent * patient with a venous leg ulcer (vlu) or with a diabetic foot ulcer (dfu) * prescription of one of the 3 dressings: urgostart plus® border, urgostart plus® pad or urgostart interface® * patient can be followed over 12 weeks by the investigator, according to his/her practices * patient able to participate in the study and complete a self-questionnaire without difficulty exclusion criteria: * hemorrhagic wound * cancerous wound * fistulous wound revealing a deep abscess * presence of dry necrosis partially or completely covering the wound bed * infected wound * osteitis * critical or acute ischemia * patient for whom a surgical procedure related to the treated wound is scheduled within 12 weeks following the inclusion visit * patient with known sensitivity to one of the studied dressings components * pregnant or breastfeeding patient * patient under the protection of justice or under guardianship or deprived of liberty
cerebellar metaplasticity in the swallowing motor system

Conditions: Swallowing; Dysphagia

Summary: dysphagia is common and leads to significant morbidity and mortality within healthcare settings. current approaches to dysphagia management involve altering the consistency of food and fluids. however, these approaches are not supported by a robust evidence base. repetitive transcranial magnetic stimulation (rtms) offers a non-invasive way to manipulate neuroelectric activity within the brain. within the swallowing motor system, rtms at a frequency of 5hertz (hz) and above is excitatory while 1hz is suppressive. cortical rtms targeting pharyngeal motor areas can alter brain activity and swallowing behaviour in healthy participants and has been shown to improve post-stroke dysphagia (psd). despite this, it has a small seizure risk. cerebellar rtms is a newer and safer technique which is more easily targeted and is effective at altering swallowing related brain activity and behaviour. recent studies have also shown it can improve psd. critically, individual responsiveness to rtms is variable, potentially reducing its effectiveness. metaplasticity whereby the brain is preconditioned with a neuroelectric stimulus before the treating stimulus is administered is a potential way of reducing variability. metaplasticity has recently been shown to improve responses within the swallowing motor system following cortical rtms. however, to date no cerebellar rtms study has applied this approach. this is a gap in our understanding which will need to be addressed. the overarching aim of the study is to develop a less variable and more effective treatment for neurogenic dysphagia. more specifically the study objectives are to establish: 1. whether 10hz cer-rtms delivered over hemispheric pharyngeal areas can induce sms metaplastic changes in healthy participants. 2. if a cerebellar rtms metaplastic stimulation protocol can affect swallowing behaviour.


Eligibility criteria:
inclusion criteria: healthy participants \> 18 years of age exclusion criteria: exclusion criteria will be the presence or a history of: 1. epilepsy 2. cardiac pacemaker 3. previous brain surgery 4. previous swallowing problems 5. the use of medication which acts on the central nervous system 6. any implanted metal in the head 7. pregnancy (self-declared)
effect of microbiome modulation by diet in functional constipation

Conditions: Constipation - Functional

Summary: current medications and behavioral modifications have limited success in the treatment of functional constipation (fc). an individualized diet based on microbiome analysis may improve symptoms in fc. in the present study, we aimed to investigate the impacts of microbiome modulation on chronic constipation. patients fulfilling rome iv criteria for functional constipation were randomized into two groups. the control group received sodium picosulfate plus conventional treatments (i.e., laxatives, enemas, increased fiber, and fluid intake). the study group underwent microbiome analysis and received an individualized diet with the assistance of a soft computing system (enbiosis biotechnology®, sariyer, istanbul). differences in patient assessment constipation-quality of life (pac-qol) score and complete bowel movements per week (cbmpw) were compared between groups after 6 week-intervention.


Eligibility criteria:
inclusion criteria: * patients fulfilling rome iv criteria for functional constipation (fc) * patients who had a colonoscopy performed within the last 5 years * patients who had a colonic transit time assessment within the last 3 months * patients who had a magnetic resonance defecography within the last 3 months exclusion criteria: * use of antibiotics, probiotics, and/or prebiotics within the last 4 weeks * gastrointestinal endoscopy within the last 4 weeks * major gastrointestinal surgery (total/segmental gastrectomy, small bowel and/or colonic resection) * cholecystectomy * inflammatory bowel diseases * celiac disease * any etiology of chronic constipation other than fc (irritable bowel syndrome, rectocele, dyssynergic defecation, opioid use) * endocrine, metabolic or neurologic disorders causing constipation (hypothyroidism, parkinson's disease, paraplegia)

Keywords: microbiome artificial intelligence diet functional bowel disorders brain-gut diseases
oxygen insufflation in microlaryngoscopies

Conditions: Hypoxia

Summary: the purpose of this project is to evaluate the efficacy of oxygen insufflation (continuous oxygen flow) to keep oxygen saturation (oxygen levels measured with a pulse oximeter \[finger device used in medicine\]) at 90% or greater in adult patients undergoing microlaryngoscopy surgery.

high flow, low pressure oxygen will be supplied in microlaryngoscopy airway surgery. these procedures are usually performed with jet ventilation (uab) or intermittent apnea (surgery centers). jet ventilation provides oxygenation with limited ventilation but come with high risks, such as barotrauma, pneumothorax, mucosa drying, and even death in the most severe cases. intermittent apnea is a nuisance for the surgeon in that surgical time is often interrupted with having to place the endotracheal tube whenever the patient's oxygen saturation levels fall. the solution is oxygen insufflation, which will give extended oxygenation times for the surgeon to operate without the inherent risks associated with jet ventilation. during the procedure, oxygen tubing will be connected to the surgeon's laryngoscope instead of the jet ventilation tubing. oxygen flows of 15 l/min will be administered through the laryngoscope to the posterior oropharynx. endotracheal tube will be placed if oxygenation deemed insufficient due to oxygen saturations of \<90%. endotracheal tube will be intermittently placed to check and correct carbon dioxide levels.

Eligibility criteria:
inclusion criteria: * adult patients undergoing microlaryngoscopy surgery without a tracheostomy exclusion criteria: * patients who have a tracheostomy

Keywords: surgery airway hypoxia prevention oxygen insufflation
study of the aortic and large arterial vessel infections

Conditions: Aortic Infections and Inflammations; Mycotic Aneurysm; Arterial Infections and Inflammations; Prosthetic Infection

Summary: aortic or large arterial vessel infections are rare but serious infections. their management is based on french and american expert opinions. the quality of evidence supporting these guidelines is low because most publications on the subject correspond to case series and few interventional studies have been performed to validate their management. however, referral centres for vascular surgery are frequently solicited to give their opinion on patients suffering from mycotic aneurysms. in addition, the last few decades have seen the improvement of vascular surgery techniques allowing the management of more and more patients, often elderly and comorbid. there has therefore been an increase in the incidence of infectious complications associated with this care. it is therefore essential to participate in research on aortic and large arterial vessel infections. for this, a monocentric cohort study seems to be an essential first step to better understand the polymorphism and complexity of these patients.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * aortic or large arterial vessel infection. the diagnosis is made on a number of criteria in favour of the diagnosis (at least 2 of the following 3 criteria): * compatible clinical presentation: local or general inflammatory signs suggestive of a deep infection (fever, chills, scar discharge, fistula, febrile abdominal pain and low back pain, ...) or per-operative finding of an infection in contact with native or prosthetic vascular tissue * and/or biological (inflammatory syndrome) and/or imaging evidence (infectious sign on native, bioprosthetic or prosthetic vascular tissue on ct and/or pet scan) in favour of the diagnosis * and/or microbiological evidence (positive serologies, blood cultures or deep samples in favour of infection) exclusion criteria: * patient who objected to participation in this protocol and data collection * pregnant woman, parturient or breastfeeding mother * person deprived of liberty by a judicial or administrative decision, * person subject to psychiatric care by virtue of articles l.3212-1 and l.3213-1 of the french public health code * person subject to a legal protection measure * person unable to give consent
exparel® for pain after tonsillectomy

Conditions: Tonsillectomy; Tonsillitis; Post-operative Pain

Summary: the purpose of this study is to determine whether liposomal bupivacaine (long acting injectable anesthetic) provides greater post operative pain relief compared to the standard post operative pain regiment for tonsillectomy patients.

subjects will be screened in the clinic when being evaluated for indications for tonsillectomy. once the decision to proceed with tonsillectomy is made, the patient will be given the information on the study, provided time to review the information and interested patients will be consented. there will be two stages in the study. the first will be the operative stage, which includes the injection during the operation. the second stage is the patient participation stage. during this stage, the patient records the amount of oral pain medication usage, oral intake after their procedure, in addition to their pain scores. these scores are recorded and brought back (or mailed in) to the clinic for collection during the follow up visit, approximately 1 month later (patients will keep records for two weeks). the patients will be freed from participation in the study after the one month visit.

Eligibility criteria:
inclusion criteria: * diagnosis of recurrent tonsillitis or bilateral tonsillar hypertrophy requiring bilateral tonsillectomy * willing and able to understand and provide written informed consent exclusion criteria: * known pregnancy * women who are currently nursing a child * history of coagulopathy; such as hemophilia or von willebrand disease, or any congenital or acquired bleeding disorder * use of anticoagulation medication during the study, i.e. aspirin, coumadin, plavix, or medications similar in class to these medications will exclude the patient from participation * inability to provide informed consent (patients under guardianship) * known hypersensitivity to local anesthetics * history of cardiac disease; such as current impaired cardiovascular function, past history of myocardial infarction, congenital heart disease, current cardiac symptoms, i.e. angina, shortness of breath, or chest pain as determined by history or review of the medical record. * history of complex pulmonary disease; such as uncontrolled asthma, chronic obstructive pulmonary disease (copd), or interstitial lung disease as determined by history or review of the medical record. * impaired renal function as documented in the medical record in the last 3 months with a serum creatinine greater than 1.2 mg/dl or glomerular filtration rate \< 60 ml/min/body surface area (bsa) as determined by history or review of the medical record. * history of or current hepatic disease as documented by liver function test abnormality in the last 3 months as determined by history or review of the medical record.

Keywords: liposomal bupivacaine
erp plus improv group therapy for ocd (improve study)

Conditions: Obsessive-Compulsive Disorder

Summary: the goal of this study is to pilot test a novel group therapy intervention for adults with ocd.

the intervention will incorporate exposure and response prevention (erp) with improvisational comedy ("improv") activities. erp is the gold-standard treatment for ocd. improv comedy is a type of theater in which actors perform without a script. this study aims to evaluate whether the intervention is helpful for reducing ocd symptoms and intolerance of uncertainty (a mechanism maintaining ocd). it will also explore whether the intervention is feasible and acceptable. during the group therapy sessions, participants will engage with improv comedy exercises that have been adapted to function as exposures for different types of ocd. participants will: * attend an erp + improv group therapy intervention (90-minute sessions for 12 weeks) * complete homework in-between sessions * answer questions * complete questionnaires.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * ability to speak and understand english * clinical diagnosis of obsessive-compulsive disorder (ocd) exclusion criteria: * current active suicidality * medical or psychiatric illness that could interfere with study participation

Keywords: behavioral therapy exrp (exposure and response prevention) erp improv comedy ocd
effect of toothpaste fortified with cyanocobalamin on vitamin b12 status

Conditions: Cobalamin Deficiency

Summary: a 3 months randomized, placebo-controlled study on the effect of toothpaste fortified with vitamin b12 on vitamin b12 status markers and related metabolic markers. the primary outcome variable is the difference in the change of methylmalonic acid after 3 months between the two study arms.


Eligibility criteria:
inclusion criteria: * adults: men and women * stable diet for at least 24 months (omnivorous or a vegan diet). exclusion criteria: * pregnancy and lactation * malabsorption disorders (crohn disease, chronic gastritis, pernicious anemia, gastric or intestinal resection) * renal diseases * liver diseases * patients with cancer (or cancer history) * pre-study treatment with vitamin b12 or folate

Keywords: cobalamin biomarkers anemia vegan diet subclinical metabolic functional markers holotranscobalamin methylmalonic acid